Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLL
Adam S. Kittai, Ying Huang, Sarah Miller, John N. Allan, Seema A. Bhat, David A. Bond, Danielle M. Brander, John C. Byrd, Julio C. Chávez, Elise A. Chong, Matthew S. Davids, Alexey V. Danilov, Wei Ding, Mark R. Dowling, Kaitlyn Dvorak‐Kornaus, Hannah Freedman, Paul J. Hampel, Carrie Ho, Steven R. Hwang, Prioty Islam, Nikita Malakhov, Matthew J. Matasar, Cecelia Miller, Zulfa Omer, Sameer A. Parikh, Erin M. Parry, Kari G. Rabe, Philipp W. Raess, Manoj Rai, Lindsey E. Roeker, Joanna Rhodes, Kerry A. Rogers, Aditi Saha, Jake Schade, Hamish W. Scott, Mazyar Shadman, Geoffrey Shouse, Alan P Skarbnik, Stephen E. Spurgeon, Deborah M. Stephens, Meghan C. Thompson, Philip A. Thompson, Yucai Wang, Max Yano, Jennifer A. Woyach
Abstract
Richter transformation (RT) is an infrequent but consequential event that can occur at any time for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL). RT is defined by the development of an aggressive lymphoma, most often diffuse large B-cell Lymphoma (DLBCL) [ 1 ]. Targeted therapies such as Bruton Tyrosine Kinase inhibitors (BTKi) and B-cell leukemia/lymphoma 2 inhibitors (BCL2i) have improved survival for patients with CLL, but not for patients with RT [ 2 , 3 ].